|
1
|
Zhenghong Zhu Z, Guoweijian Zhangning,
Caiyunyun Yingjiangshan and Xiaomi : Retrospective study of
predictors of bone metastasis in colorectal cancer patients. J Bone
Oncol. 9:25–28. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kobayashi Y, Shida D, Boku N, Yasui K,
Nakamura Y, Kudose Y, Imaizumi J and Kanemitsu Y: Prognostic
factors of bone metastases from colorectal cancer in the era of
targeted therapy. Dis Colon Rectum. 66:401–409. 2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Rocha MM, Dariva I, Zornoff GC, De
Laurentis GS, Mendes GC, Santana MG, de Miguel GC, Ferreira RS,
Sciani JM and Priolli DG: A new therapeutic approach for bone
metastasis in colorectal cancer: Intratumoral melittin. J Venom
Anim Toxins Incl Trop Dis. 28(e20210067)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ma CX, Guan X, Wei R, Wang S, Quan JC,
Zhao ZX, Chen HP, Liu Z, Jiang Z and Wang XS: The distinction of
clinicopathological characteristics, treatment strategy and outcome
in colorectal cancer patients with synchronous vs. metachronous
bone metastasis. Front Oncol. 10(974)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Fornetti J, Welm AL and Stewart SA:
Understanding the bone in cancer metastasis. J Bone Miner Res.
33:2099–2113. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hong S, Youk T, Lee SJ, Kim KM and Vajdic
CM: Bone metastasis and skeletal-related events in patients with
solid cancer: A Korean nationwide health insurance database study.
PLoS One. 15(e0234927)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Suresh Babu MC, Garg S, Lakshmaiah KC,
Babu KG, Kumar RV, Loknatha D, Abraham LJ, Rajeev LK, Lokesh KN,
Rudresha AH and Rao SA: Colorectal cancer presenting as bone
metastasis. J Cancer Res Ther. 13:80–83. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Li A, Käsmann L, Rades D and Fu C: A
scoring system to predict the development of bone metastasis after
radical resection of colorectal cancer. Anticancer Res.
37:5169–5172. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ilieva N, Tashkova D, Staykov D, Serteva
D, Feodorova Y, Mehterov N, Mollova A and Bachurska S:
Immunohistochemical expression of CK20, CK7, and CDX2 in colorectal
carcinoma in correlation with pathomorphological characteristics.
Folia Med (Plovdiv). 64:214–220. 2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Korphaisarn K, Sukhokanjanachusak K,
Pongpaibul A, Chinswangwatanakul V and Akewanlop C: Loss of CDX-2
expression is an independent poor prognostic biomarker in patients
with early-stage deficient mismatch repair colorectal cancer. Asia
Pac J Clin Oncol. 18:249–258. 2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Cowan ML, Li QK and Illei PB: CDX-2
expression in primary lung adenocarcinoma. Appl Immunohistochem Mol
Morphol. 24:16–19. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Girardo C, Fakhri N, Khokhar H, Jetly R
and Bhalla R: CDX2 expression in primary and metastatic prostatic
adenocarcinoma: A retrospective study. Am J Clin Pathol. 154 (Suppl
1):S59–S60. 2020.
|
|
13
|
Simkens LH, van Tinteren H, May A, ten
Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec
Z, van der Torren AM, et al: Maintenance treatment with
capecitabine and bevacizumab in metastatic colorectal cancer
(CAIRO3): A phase 3 randomised controlled trial of the Dutch
colorectal cancer group. Lancet. 385:1843–1852. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wang H, Shan X, Zhang M, Qian K, Shen Z
and Zhou W: Nomograms for predicting overall survival in colorectal
cancer patients with metastasis to the liver, lung, bone, and
brain. Cancer Causes Control. 34:1059–1072. 2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Liu Z, Xu Y, Xu G, Baklaushev VP,
Chekhonin VP, Peltzer K, Ma W, Wang X, Wang G and Zhang C: Nomogram
for predicting overall survival in colorectal cancer with distant
metastasis. BMC Gastroenterol. 21(103)2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Park HS, Chun YJ, Kim HS, Kim JH, Lee CK,
Beom SH, Shin SJ and Ahn JB: Clinical features and KRAS mutation in
colorectal cancer with bone metastasis. Sci Rep.
10(21180)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Díez-Alonso M, Mendoza-Moreno F,
Gómez-Sanz R, Matías-García B, Ovejero-Merino E, Molina R,
Soto-Schütte S, San Juan A and Gutierrez-Calvo A: Prognostic value
of KRAS gene mutation on survival of patients with peritoneal
metastases of colorectal adenocarcinoma. Int J Surg Oncol.
2021(3946875)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Díez-Alonso M, Mendoza-Moreno F,
Jiménez-Álvarez L, Nuñez O, Blazquez-Martín A, Sanchez-Gollarte A,
Matías-García B, Molina R, San-Juan A and Gutierrez-Calvo A:
Prognostic factors of survival in stage IV colorectal cancer with
synchronous liver metastasis: Negative effect of the KRAS mutation.
Mol Clin Oncol. 14(93)2021.PubMed/NCBI View Article : Google Scholar
|
